



## **FOR IMMEDIATE RELEASE**

**LAUREATE PHARMA SPONSORS LIVE WEBCAST PRESENTED BY BIOPHARM INTERNATIONAL**

### **DEVELOPMENT OF A THIRD-GENERATION RADIOLABELED ANTIBODY FOR THERAPY OF PROSTATE CANCER**

PRINCETON, NJ – June 1, 2006– Laureate Pharma, Inc., a full service biopharmaceutical development and protein production company, is sponsoring a live webcast presented by *BioPharm International* on “Development Of A Third-Generation Antibody For Therapy Of Prostate Cancer” that will be held on June 8<sup>th</sup> at 2 PM EDT. The webcast will include presentations by distinguished experts from Cytogen Corporation, Laureate Pharma, Inc., and Memorial Sloan Kettering Cancer Center and will be moderated by BioPharm International ([www.BioPharmInternational.com](http://www.BioPharmInternational.com).)

The development of radiolabeled therapeutic antibodies is a sophisticated process involving both selection of an isotope with optimal radiation properties and secure mechanisms of isotope attachment. Such antibodies have enhanced potency in cancer therapy, directing potent radiation to specific areas of disease. Process development and cGMP manufacturing of these entities for clinical trials pose logistical challenges best addressed by a team approach, involving more than one company on the route from "concept to clinic". The experts, working together as a multi-company collaboration, overcame challenges and produced a new radiolabeled antibody therapeutic. It combines a PSMA-specific targeting antibody with a high-affinity chelator and a beta-emitting isotope with desirable properties for irradiation of metastatic sites in prostate cancer.

The experts will be discussing topics such as selection of targeting antibody; The rationale for choice of radioisotope; Design and properties of chelators for optimal attachment of radio-metallic isotopes to antibodies; Understanding process development and cGMP manufacturing of radiolabeled antibodies; Preclinical design considerations for radiolabeled antibodies; Value of multi-company collaboration to address logistical challenges associated with a complex radiolabeled biopharmaceutical and the value of radiolabeled antibodies in cancer therapy. The audience will have an opportunity to pose their questions to the panel of experts during the real-time Q&A session following the presentations. Those who are interested in participating in the webcast are encouraged to register for the event through the website [www.laureatepharma.com](http://www.laureatepharma.com) or [www.BioPharmInternational.com/RadioLabels](http://www.BioPharmInternational.com/RadioLabels).

#### **About Laureate Pharma, Inc.**

Laureate Pharma, [www.laureatepharma.com](http://www.laureatepharma.com), located in Princeton, NJ provides superior bioprocessing services that accelerate new products from development through production. Laureate Pharma is a partner company of Safeguard Scientifics, Inc. (NYSE: SFE), [www.safeguard.com](http://www.safeguard.com), which provides growth capital as well as a range of strategic, operational and management resources to Laureate Pharma and their other partner companies. For more information contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development (609) 919-3400 or [info@laureatepharma.com](mailto:info@laureatepharma.com)